Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

This was a phase III, randomized, double-blind, placebo-controlled, multicenter trial.

Who Took Part

The abstract describes 477 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Eligible patients with ADHF were randomized to receive a 1-h infusion of either rhANP or placebo at a ratio of 3:1 in combination with standard therapy.

Overall, 477 patients were randomized: 358 (93 catheterized) patients received rhANP and 118 (28 catheterized) received placebo.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

The patients were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

As a double-blind ANP (Atrial Natriuretic Peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with ANP (Atrial Natriuretic Peptide) could be set against what happens without it.

More than one site took part, so the patients came from several places.

What Was Measured

Topics PubMed links to this paper include Acute Disease, Atrial Natriuretic Factor, Cardiovascular Agents and Heart Failure.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 477 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2016 (Medicine), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.